TY  - BOOK
AU  - Hamasaki,Toshimitsu
AU  - Asakura,Koko
AU  - Evans,Scott R.
AU  - Ochiai,Toshimitsu
ED  - SpringerLink (Online service)
TI  - Group-Sequential Clinical Trials with Multiple Co-Objectives
T2  - JSS Research Series in Statistics,
SN  - 9784431559009
AV  - QA276-280 
U1  - 519.5 23
PY  - 2016///
CY  - Tokyo
PB  - Springer Japan, Imprint: Springer
KW  - Mathematical statistics
KW  - Statistics
KW  - Statistical Theory and Methods
KW  - Statistics for Life Sciences, Medicine, Health Sciences
KW  - Statistics for Social Science, Behavorial Science, Education, Public Policy, and Law
N1  - 1. Introduction -- 2. Early Stopping for Efficacy in Clinical Trials with multiple co-primary endpoints -- 3. Sample size recalculation based on observed effects at interim -- 4. Early stopping for futility in Clinical Trials with multiple co-primary endpoints -- 5. Early stopping for futility or Efficacy in Clinical Trials with multiple co-primary endpoints -- 6. Clinical Trials with multiple primary endpoints -- 7. Group-sequential designs for three-arm noninferiority clinical trials -- 8. Further development: topics not covered in this book
N2  - This book focuses on group sequential methods for clinical trials with co-primary endpoints based on the decision-making frameworks for: (1) rejecting the null hypothesis (stopping for efficacy), (2) rejecting the alternative hypothesis (stopping for futility), and (3) rejecting the null or alternative hypothesis (stopping for either futility or efficacy), where the trial is designed to evaluate whether the intervention is superior to the control on all endpoints. For assessing futility, there are two fundamental approaches, i.e., the decision to stop for futility based on the conditional probability of rejecting the null hypothesis, and the other based on stopping boundaries using group sequential methods. In this book, the latter approach is discussed. The book also briefly deals with the group sequential methods for clinical trials designed to evaluate whether the intervention is superior to the control on at least one endpoint. In addition, the book describes sample size recalculation and the resulting effect on power and type I error rate. The book also describes group sequential strategies for three-arm clinical trials to demonstrate the non-inferiority of experimental intervention to actively control and to assess the assay sensitivity to placebo control
UR  - https://doi.org/10.1007/978-4-431-55900-9
ER  -